Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Advanced Micro Devices (AMD) vs TG Therapeutics Inc (TGTX) Price & Performance

Advanced Micro DevicesTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Advanced Micro Devices vs TG Therapeutics Inc — how do they compare? Advanced Micro Devices trades at $486.72 (market cap $774.32B), while TG Therapeutics Inc trades at $49.6 (market cap $7.64B). The key difference: Advanced Micro Devices is far larger — about 101.4× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.

AMDTGTX
Market Cap
$774.32B$7.64B
Sector
TechnologyHealth
52-Week High
$580.91$59.06
52-Week Low
$151.14$26.94
Enterprise Value
$765.48B$7.84B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Advanced Micro Devices

AMD's stock trades at $469.56, down 2.86% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.66, and shows robust revenue growth, with 2025 revenue reaching $34.64 billion and net income of $4.34 billion. Valuation ratios remain elevated, with a P/E of 121 and P/S of 18.94, reflecting high market expectations amid surging AI demand.

Outlook is supported by AI-driven growth and consistent earnings beats, but risks include intense competition and rich valuations. Analysts maintain a bullish consensus with a $619.54 price target, though near-term volatility may persist due to technical pressure and macroeconomic factors.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Advanced Micro Devices

Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.

Read more on AMD

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX